"","Num","POD","SD","%","Genes","KE"
"GO:0010463","2","1.29149334736446e-06","1.16477786152765","16.67","fgfr1a, tbx1","INCREASED PROLIFERATION OF MESENCHYMAL CELLS"
"ABNORMAL FORM OF THE VERTEBRAL BODIES","4","1.58594832399041e-06","0.394872250767038","12.12","bmp1a, fgfr1a, hspa9, whsc1","CLONAL EXPANSION/CELL PROLIFERATION TO FORM ALTERED HEPATIC FOCI AHF"
"GO:0048469","4","1.612753825129e-06","0.39374256074277","16.67","btk, cdkn1ca, cebpa, fgfr1a","INCREASED OOCYTE MATURATION"
"ABNORMAL HYPOTHALAMUS PHYSIOLOGY","2","1.66642269945019e-06","1.24304963201973","22.22","fgfr1a, pik3ca","REDUCED PROSTAGLANDIN E2 CONCENTRATION HYPOTHALAMUS; DECREASE E2 BLOOD CONCENTRATIONS AT HYPOTHALAMUS"
"GO:0019882","4","2.22496034291581e-06","0.404597271245772","6.78","psma2, psmb5, psmc4, psmd10","GENERATION OF NOVEL EPITOPES  ANTIGEN PRESENTATION"
"SMOOTH MUSCLE CELL PROLIFERATION","4","3.38280326727974e-06","0.311110159865823","15.38","ddx39b, igf1, mmp9, rps6kb1b","HYPERTROPHY/HYPERPLASIA SMOOTH MUSCLE"
"GO:1903009","4","3.39102786110848e-06","0.467954922685595","11.76","psma2, psmb5, psmc1b, psmc4","DECREASE GTPCH-1"
"CTOME CELLULAR RESPONSE TO HYPOXIA","6","3.92506470095612e-06","0.271530258211281","13.95","psma2, psmb5, psmc1b, psmc4, psmd10, uba52","N/A HYPOXIA"
"GO:0008283","2","4.15763590880769e-06","0.791884600371426","22.22","mif, tacc3","PROLIFERATION CELL PROLIFERATION IN THE ABSENCE OF CYTOTOXICITY; ACTIVATION/PROLIFERATION T-CELLS; ALTERATIONS CELLULAR PROLIFERATION / HYPERPLASIA; INCREASE PROLIFERATION LEYDIG CELL; INCREASE MITOGENIC CELL PROLIFERATION HEPATOCYTES; INCREASE HYPERTROPHY AND PROLIFERATION FOLLICULAR CELL; INCREASE REGENERATIVE CELL PROLIFERATION CORNEAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION FORESTOMACH EPITHELIAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION HEPATOCYTES; INCREASE REGENERATIVE CELL PROLIFERATION UROTHELIAL CELLS; INCREASE CELL PROLIFERATION; INCREASE PROLIFERATION OF GOBLET CELLS; INCREASED HYPERTROPHY AND PROLIFERATION FOLLICULAR CELL; PROLIFERATION/CLONAL EXPANSION SMOOTH MUSCLE; INCREASED CELLULAR PROLIFERATION / HYPERPLASIA OF ACINAR CELLS; PROLIFERATION/CLONAL EXPANSION ABERRANT BASAL CELLS; INCREASED CELL PROLIFERATION MESOTHELIUM; INCREASE CELL PROLIFERATION EPITHELIAL CELLS"
"ABNORMALITY OF THE ENDOMETRIUM","2","4.45881467477453e-06","0.940807976035021","18.18","msh6, pik3ca","INCREASED HYPERPLASIA GLANDULAR EPITHELIAL CELLS OF ENDOMETRIUM; INCREASE HYPERPLASIA GLANDULAR EPITHELIAL CELLS OF ENDOMETRIUM; INCREASED ADENOSQUAMOUS CARCINOMAS OF ENDOMETRIUM"
"ELECTRON TRANSPORT CHAIN","6","4.76063595832619e-06","0.207616837841251","8.82","cdk1, cox7c, cyp1a, ndufb2, ndufv2, phgdh","DISRUPTION MITOCHONDRIAL ELECTRON TRANSPORT CHAIN"
"TUBE FEEDING","3","4.80735216738803e-06","0.640375887079112","17.65","dnm1l, fgfr1a, ppp2r1a","INHIBITION FEEDING"
"GO:0006281","16","4.83445794257354e-06","0.0720864515760881","18.82","axin2, cdk1, cdk7, h2afx, hsf1, msh6, nploc4, ogg1, pola1, pold3, polr2l, rchy1, rfc3, stub1, uba52, whsc1","N/A INSUFFICIENT OR INCORRECT DNA REPAIR; INCREASED INSUFFICIENT REPAIR OR MIS-REPAIR OF PRO-MUTAGENIC DNA ADDUCTS; OVERWHELMED MITOCHONDRIAL DNA REPAIR MECHANISMS; INCREASED DNA DAMAGE-REPAIR"
"G OOCYTE MEIOSIS","5","4.83812125524602e-06","0.279332730152496","12.5","cdk1, igf1, igf1ra, mapk1, ppp2r1a","REDUCED MEIOTIC PROPHASE I/METAPHASE I TRANSITION OOCYTE"
"GO:0004882","10","4.91492556733943e-06","0.119070696834368","28.57","casp8, cdk1, cdk7, igf1, mapk1, ncoa4, pou2f1b, rchy1, smad3b, stub1","N/A ANDROGEN RECEPTOR ANTAGONISM; AGONISM ANDROGEN RECEPTOR; DECREASED ANDROGEN RECEPTOR ACTIVITY; ACTIVATION ANDROGEN RECEPTOR"
"CYTOPLASMIC RIBOSOMAL PROTEINS","10","5.03997797558313e-06","0.116788415264885","6.94","rpl13a, rpl19, rpl21, RPL29, rpl39, rps26l, rps3a, rps6kb1b, rps9, uba52","OCCURRENCE CYTOPLASMIC VACUOLIZATION PODOCYTE"
"GO:0030545","7","5.04491235198456e-06","0.19083529288916","11.86","bmp1a, fgf3, fsta, igf1, inhbab, mif, wnt3a","DESENSITIZATION NICOTINIC ACETYLCHOLINE RECEPTOR"
"ABNORMAL SOCIAL BEHAVIOR","4","5.20935215252143e-06","0.261022014856939","15.38","ndufv2, pola1, tars, uchl1","ABNORMAL FORAGING ACTIVITY AND BEHAVIOR"
"GO:0007059","5","5.42731535390881e-06","0.279722355002509","11.36","axin2, nup62l, tacc3, ttk, zw10","INCREASED CHROMOSOME MISSEGGREGATION"
"GO:0022414","6","5.63297426223635e-06","0.202360229779587","16.67","fsta, h2afx, igf1rb, msh6, paqr7b, ttk","INCREASED REPRODUCTIVE SUCCESS"
"SOMATIC MUTATION","7","6.24953293551324e-06","0.247279418530956","8.33","axin2, casp8, cebpa, fgfr1a, msh6, nras, pik3ca","INCREASED INDUCED MUTATIONS IN CRITICAL GENES; INCREASE MUTATIONS; INCREASE MUTATIONS IN CRITICAL GENES"
"CTOME REGULATED NECROSIS","7","6.25767240121782e-06","0.206657353000358","33.33","birc2, casp3b, casp8, flot2a, stub1, tradd, uba52","INCREASE NECROSIS TERMINAL BRONCHIOLAR CELLS"
"CTOME SIGNALING BY TYPE 1 INSULIN LIKE GROWTH FACTOR 1 RECEPTOR IGF1R","6","6.49864139316641e-06","0.280796424563638","46.15","fgf3, fgfr1a, igf1, igf1ra, nras, pik3ca","INCREASED IGF-1 MOUSE"
"GO:0030163","21","6.93259775508975e-06","0.0640100943757427","13.73","birc2, casp8, cdk1, cebpa, ctsk, cyp51, gna12a, hspa5, mapk9, nploc4, psma2, psmb5, psmc4, psmd10, rchy1, stub1, uba52, ube4b, uchl1, usp14, vldlr","INCREASED CATABOLISM OF MUSCLE PROTEIN"
"NEOPLASM OF THE SKIN","5","7.06612077965311e-06","0.377757030977103","15.15","fgfr1a, msh6, nras, pik3ca, tars","SENSITISATION SKIN"
"GO:0043542","4","7.48820279069131e-06","0.405695837729518","11.43","cyp1b1, fgfr1a, pik3ca, tek","INCREASED MIGRATION ENDOTHELIAL CELLS"
"GO:0042701","8","7.498862316088e-06","0.154119336221496","23.53","ccna2, cdk1, igf1, igf1ra, igf1rb, mapk1, mapk9, pik3ca","DECREASED PROGESTERONE FROM CORPUS LUTEUM"
"DECREASED FERTILITY","4","7.76752736350045e-06","0.57813802018423","5.26","fgfr1a, foxa2, gata4, stub1","IMPAIRED FERTILITY; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; REDUCTION CUMULATIVE FECUNDITY AND SPAWNING; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; DECREASED TESTOSTERONE"
"GO:0070265","3","7.82443724283724e-06","0.528809626355362","27.27","birc2, casp8, dnm1l","INCREASE TISSUE DEGENERATION NECROSIS & ATROPHY; INCREASED ONCOTIC NECROSIS"
"IMMUNOLOGIC HYPERSENSITIVITY","4","8.24281385524424e-06","0.409667581291854","17.39","casp8, cdkn1ca, fgfr1a, tbx1","INCREASE ALLERGIC RESPIRATORY HYPERSENSITIVITY RESPONSE"
"DNA DAMAGE RESPONSE","4","9.0960096206047e-06","0.350042056452918","6.9","casp3b, casp8, cdk1, h2afx","INCREASED DNA DAMAGE-REPAIR"
"GO:0007249","8","9.20107025278143e-06","0.171714756617088","18.6","birc2, btk, casp8, nfkb1, nup62l, tradd, uba52, wls","INHIBITION NUCLEAR FACTOR KAPPA B NF-KB"
"GO:0006412","15","1.03131432422335e-05","0.0695243627638531","13.89","eif2b3, eif3g, eif3ja, eif4a1a, eif4a1b, eif4bb, rpl13a, rpl19, rpl21, RPL29, rpl39, rps26l, rps3a, rps9, uba52","ALTERED PROTEIN PRODUCTION"
"GO:0007051","3","1.03658370656404e-05","0.437934019890357","11.11","nup62l, tacc3, ttk","DISORGANIZATION SPINDLE"
"ABNORMALITY OF THE OVARY","6","1.06520582489252e-05","0.286935997565029","10.53","eif2b3, fgfr1a, gata4, insrb, msh6, pik3ca","REDUCED PROSTAGLANDINS OVARY"
"GO:0070330","3","1.08075425737481e-05","0.276467249044645","37.5","cyp1a, cyp1b1, cyp3c1","REDUCTION IN OVARIAN GRANULOSA CELLS AROMATASE CYP19A1; INHIBITION AROMATASE; DECREASED AROMATASE CYP19A1 MRNA"
"HEPATOCELLULAR CARCINOMA","3","1.12661478274049e-05","0.500709868546811","23.08","casp8, msh6, pik3ca","FORMATION HEPATOCELLULAR AND BILE DUCT TUMORS; INCREASE ADENOMAS/CARCINOMAS HEPATOCELLULAR; TUMORIGENESIS HEPATOCELLULAR CARCINOMA"
"JNK CASCADE","6","1.15778004578377e-05","0.181625137944033","27.27","igf1ra, mapk9, mmp13a, ptpn1, uba52, ube2nb","ACTIVATION JNK"
"GO:1903008","4","1.15805597832732e-05","0.362373985754489","30.77","cdk1, ctsk, dnm1l, pelo","DISRUPTION LYSOSOME"
"ARYL HYDROCARBON RECEPTOR PATHWAY","3","1.19837408636349e-05","0.292123398371744","6.25","ahr1b, cyp1a, cyp1b1","UP REGULATION CYP1A1; ACTIVATION AHR"
"REGULATION OF PH","3","1.2015176838312e-05","0.357796114639832","21.43","atp6v1c1a, atp6v1e1b, mapk1","DECREASE INTRACELLULAR PH"
"HYPERACTIVITY","11","1.21748337724484e-05","0.123887323933418","22","cdkn1ca, fgfr1a, gata4, glud1a, igf1, mapk1, msh6, pik3ca, pola1, ppp2r1a, tbx1","INDUCTION ATAXIA PARALYSIS OR HYPERACTIVITY; INCREASED ATAXIA PARALYSIS OR HYPERACTIVITY; N/A ATAXIA PARALYSIS OR HYPERACTIVITY"
"REGULATION OF WNT SIGNALING PATHWAY","11","1.21756610486637e-05","0.117612664206933","13.92","axin2, csnk1g2a, nfkb1, ppp2r1a, psma2, psmb5, psmc1b, psmc4, psmd10, wls, wnt3a","INHIBITION WNT PATHWAY"
"ABNORMALITY OF THE MITOCHONDRION","3","1.22913650547938e-05","0.349392693486314","2.38","dnm1l, ndufv2, pdhx","INJURY MITOCHONDRIA; DAMAGING MITOCHONDRIA; N/A MITOCHONDRIAL DYSFUNCTION 1"
"GO:0016310","22","1.23042298772714e-05","0.0524949385357354","17.6","acvr2b, btk, cdk1, cdk7, cdkn1ca, csf1ra, csnk1g2a, csnk2a2a, fgfr1a, igf1ra, igf1rb, insra, insrb, mapk1, mapk9, nme2b.2, nme7, pak2b, pik3ca, rps6kb1b, tek, ttk","ACTIVATION SP1"
"APOPTOSIS","7","1.26620056683976e-05","0.191306889609071","12.5","birc2, casp3b, casp8, igf1, igf1ra, nfkb1, tradd","INCREASED APOPTOSIS ADENOMAS/CARCINOMAS FOLLICULAR CELL"
"REGULATION OF PROTEOLYSIS","17","1.29030256018509e-05","0.0778400572375469","15.18","adora2aa, birc2, casp8, cebpa, f3a, gna12a, hsf1, mapk9, mmp9, psmc1b, psmc4, psmd10, rchy1, stub1, tradd, usp14, wnt3a","IMPAIRED PROTEOSTASIS"
"RESPONSE TO ESTRADIOL","7","1.31412811651116e-05","0.118399215082719","23.33","casp3b, casp8, ccna2, cyp1a, hsf1, ogg1, slc6a4a","REDUCTION PLASMA 17BETA-ESTRADIOL CONCENTRATIONS"
"UPPER MOTOR NEURON DYSFUNCTION","19","1.40989944228762e-05","0.0617719601474193","4.01","atp6v1e1b, cyp26c1, dnm1l, eif2b3, fgfr1a, impdh1b, mdh1aa, msh6, ndufv2, nup62l, pdhx, phgdh, pik3ca, pitx3, pola1, rnaseh2b, stub1, tars, uchl1","DECREASE HISTAMINERGIC NEURON EXCITATION; OCCURRENCE CYTOPLASMIC VACUOLIZATION BILE DUCT CELL; OCCURRENCE CYTOPLASMIC VACUOLIZATION KUPFFER CELL"
"GO:0016055","4","1.43578641802511e-05","0.276664957114309","17.39","axin2, fzd7a, wls, wnt3a","ALTERATION WNT PATHWAY"
"GO:0044703","26","1.45038849140103e-05","0.0430953039184402","22.41","adra2c, birc2, cad, cdk1, crhr1, crtap, cyp1a, drd1b, fsta, h2afx, hsd11b2, hsf1, igf1, inhbab, mapk1, mmp9, nhp2l1b, nup62l, paqr7b, pparda, RPL29, rpl39, rps6kb1b, slc6a4a, thraa, ttk","N/A REPRODUCTIVE FAILURE"
"GO:0050673","14","1.47057285377731e-05","0.0981088302709263","17.07","agtr1b, cdkn1ca, f3a, f3b, fgfr1a, fsta, igf1, mapk1, nme2b.2, nras, pparda, tbx1, tek, wnt3a","INCREASE REGENERATIVE CELL PROLIFERATION TUBULAR EPITHELIAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION TERMINAL BRONCHIOLAR EPITHELIAL CELLS"
"GO:0005102","29","1.50721458366733e-05","0.0400930242514654","13.94","adora2aa, adra2c, agtr1b, bmp1a, casp3b, casp8, cdk7, drd2b, f11r.1, fgf3, fgfr1a, flot2a, fsta, gna12a, gnat2, igf1, igf1ra, inhbab, insra, insrb, mif, ncoa4, nup62l, ptpn1, stub1, tradd, uchl1, wls, wnt3a","DECREASED TESTOSTERONE BINDING TO ANDROGEN RECEPTOR HYPOTHALAMUS"
"GO:0000003","41","1.50813898762642e-05","0.0268920503597049","20.2","adra2c, birc2, cad, casp3b, casp8, cdk1, cdkn1ca, cebpa, crhr1, crtap, cyp1a, drd1b, e2f7, fsta, gata4, h2afx, hsd11b2, hsd17b2, hsf1, hspa5, igf1, inhbab, insra, insrb, ldha, mapk1, mmp9, msh6, ncoa4, nhp2l1b, nup62l, oprl1, paqr7b, pparda, RPL29, rpl39, rps6kb1b, slc6a4a, thraa, ttk, zw10","REDUCED REPRODUCTIVE SUCCESS; REPRODUCTIVE FAILURE"
"GO:0015908","5","1.54204834233506e-05","0.215355375921021","22.73","atp5j, drd2b, mif, pparda, rps6kb1b","INCREASED FA INFLUX"
"BREAST CANCER PATHWAY","11","1.59992858668652e-05","0.115857795522784","9.65","axin2, e2f3, fgf3, fgfr1a, igf1, igf1ra, mapk1, nras, pik3ca, rps6kb1b, wnt3a","N/A BREAST CANCER"
"DECREASED BODY WEIGHT","31","1.61593807228769e-05","0.0378658400668497","13.72","atp6v1e1b, birc2, bmp1a, btk, casp8, cdkn1ca, cyp24a1, dnm1l, fgfr1a, fip1l1b, gata4, hsd11b2, hsd3b7, igf1, igf1ra, insrb, msh6, ndufv2, nfkb1, nos1, nup62l, orc6, pdhx, pdx1, phgdh, pik3ca, pola1, rps26l, tbx1, tpm3, whsc1","DECREASED BODY WEIGHT"
"GO:0042116","4","1.68287072307771e-05","0.324172794481765","26.67","cebpa, kars, mif, mmp13a","INCREASED ACTIVATION AND RECRUITMENT OF HEPATIC MACROPHAGES KUPFFER CELLS"
"GO:0006633","4","1.68891282654964e-05","0.19280722014562","13.79","cyp1a, cyp3c1, mif, ptgesl","SYNTHESIS DE NOVO FA; INCREASED DE NOVO FA SYNTHESIS; INCREASED DE NOVO FA SYNTHESIS"
"GO:0005125","3","1.72109876030131e-05","0.593011683944259","12","bmp1a, inhbab, mif","ACTIVATION INFLAMMATORY CYTOKINES CHEMOKINES CYTOPROTECTIVE GENE PATHWAYS"
"GO:0045333","9","1.74017448424452e-05","0.144532711012372","12.5","cdk1, cox7c, cyp1a, mdh1aa, ndufb2, ndufv2, pik3ca, sirt3, suclg2","INCREASE OXIDATIVE METABOLISM"
"GO:0001816","22","1.74296692727956e-05","0.0544525376537687","18.33","birc2, btk, casp8, cebpa, cyp1b1, drd2b, f11r.1, fgfr1a, gata4, hsf1, igf1, inhbab, kars, mif, mmp13a, nfkb1, nploc4, polr2l, polr3d, polr3f, ptpn6, wnt3a","NON-NEURONAL PRODUCTION OF TNF EPITHELIAL IRRITATION; PRODUCTION OF NERVE GROWTH FACTOR  EPITHELIAL IRRITATION; NON-NEURONAL PRODUCTION OF IL-8/CXCL1 EPITHELIAL IRRITATION"
"GO:0048856","4","1.77344726290029e-05","0.216664409540895","33.33","igf1ra, igf1rb, insra, insrb","ALTERED NEUROANATOMY"
"ABNORMALITY OF REPRODUCTIVE SYSTEM PHYSIOLOGY","18","1.79912351853876e-05","0.0725144317662302","17.48","ahr1b, cdkn1ca, dnm1l, eif2b3, fgfr1a, fip1l1b, foxa2, gata4, igf1, impdh1b, lss, nras, phgdh, pik3ca, pola1, rras, stub1, uchl1","N/A IMPAIRMENT OF REPRODUCTIVE CAPACITY"
"ABNORMALITY OF THE BLADDER","6","1.82049579565259e-05","0.159139878156884","11.54","cdkn1ca, glud1a, hspa9, pik3ca, stub1, tbx1","REDUCED POSTERIOR SWIM BLADDER INFLATION; REDUCED ANTERIOR SWIM BLADDER INFLATION; INCREASE URINARY BLADDER CALCULI"
"GO:0009790","31","1.84550977987668e-05","0.0411168967414436","18.34","acvr2b, axin2, casp3b, casp8, cdk1, cdkn1ca, cebpa, e2f7, fgfr1a, foxa2, gata4, gna12a, hsd17b2, hsf1, igf1, inhbab, insra, insrb, lhx2b, mapk1, mmp13a, mmp9, pdx1, pelo, phgdh, psmc4, rnaseh2b, tbx1, tbx5a, wls, wnt3a","DEFECT OF EMBRYOGENESIS"
"ABNORMAL OVARIAN MORPHOLOGY","4","1.85947328258264e-05","0.481252707695715","10.81","fgfr1a, gata4, insrb, pik3ca","PROMOTION OVARIAN GRANULAR CELL TUMORS; DECREASED OVARIAN E2; PROMOTION OVARIAN ADENOMAS"
"PYRUVATE METABOLIC PROCESS","5","1.87697091954816e-05","0.203800012785811","8.93","igf1, insrb, ldha, nup62l, pdhx","INHIBITION 4-HYDROXYPHENYL-PYRUVATE DIOXYGENASE HPPD ENZYME"
"ABNORMALITY OF THE PITUITARY GLAND","8","1.94045828033533e-05","0.198471032089371","16.67","btk, cdkn1ca, fgfr1a, foxa2, gata4, msh6, pik3ca, pola1","INCREASED ADENOMAS PITUITARY"
"ENDOMETRIAL CANCER","5","2.25500392096804e-05","0.340323864580698","7.35","axin2, fgfr1a, mapk1, nras, pik3ca","INCREASE ENDOMETRIAL ADENOCARCINOMAS"
"GO:0030154","6","2.32571629677078e-05","0.190334835418469","9.23","fgf3, foxa2, fsta, paqr7b, pparda, thraa","DIFFERENTIATION OF MYOFIBROBLAST"
"GO:0007568","14","2.36289817518206e-05","0.0822793020277496","16.28","cdk1, cdkn1ca, cyp1a, gclm, h2afx, mapk1, mif, msh6, nup62l, ogg1, pdx1, pitx3, rps6kb1b, sirt3","ACCELERATED AGING"
"ABNORMALITY OF BLOOD AND BLOOD FORMING TISSUES","28","2.38068244791367e-05","0.0390207094249374","6.93","atp6v1e1b, birc2, btk, cad, casp8, cebpa, ctsk, cyp26c1, dnm1l, fip1l1b, hsd3b7, hspa9, mapk1, msh6, ndufv2, nfkb1, nos1, nras, pdx1, phgdh, pik3ca, rnaseh2b, rps26l, rras, tars, tbx1, tek, thraa","DAMAGING RED BLOOD CELLS; HEMOLYSIS"
"GO:0005515","8","2.40202390239698e-05","0.107580802000322","17.02","axin2, bmp1a, e2f7, nup62l, smad3b, tbx1, tbx5a, thraa","BINDING SH-/SELEN-PROTEINS; COVALENT BINDING PROTEIN"
"INCREASED SUSCEPTIBILITY TO FRACTURES","6","2.41288794755189e-05","0.252863552140149","17.14","crtap, ctsk, fgfr1a, nras, tpm3, wnt3a","INCREASED DISEASE SUSCEPTIBILITY"
"GO:0001775","31","2.4207535668558e-05","0.0317321566758823","15.82","adora2aa, adra2c, ahr1b, atp6v0ca, btk, casp3b, casp8, cebpa, f11r.1, flot2a, gclm, gna12a, igf1, impdh1b, inhbab, kars, mapk1, mif, mmp13a, mmp9, msh6, nfkb1, nme2b.2, nras, pik3ca, psma2, ptgesl, ptpn6, sart1, whsc1, wnt3a","ACTIVATION DENDRITIC CELLS"
"GO:0005488","154","2.48931364153716e-05","0.00685533691842482","14.31","acvr2b, adra2c, ahr1b, atf5b, axin2, birc2, bmp1a, btk, cad, casp8, cdc42l, cdk1, cdk7, cebpa, cpsf1, cpsf6, crhr1, crtap, csf1ra, csnk1g2a, csnk2a2a, cyp1a, cyp1b1, cyp24a1, cyp26c1, cyp3c1, cyp51, ddx39b, dnm1l, e2f3, e2f7, eci2, eif2b3, eif3g, eif3ja, eif4a1a, eif4a1b, eif4bb, f11r.1, fgf3, fgfr1a, fip1l1b, foxa2, fsta, fzd7a, gata4, gclm, glra4a, gna12a, gnat2, gosr2, h2afx, hsf1, hspa5, hspa9, htatsf1, htr1d, igf1, igf1ra, igf1rb, igfbp1a, imp3, imp4, impdh1b, inhbab, insra, insrb, kars, lhx2b, llgl2, lman2, lsm8, mapk1, mapk9, mmp11a, mmp13a, mmp14a, mmp17a, mmp9, msh6, nat10, ndufv2, nfkb1, nhp2l1b, nme2b.2, nme7, nol6, nos1, npffr1l2, nploc4, npy2rl, nras, nup62l, ogg1, opn5, oprl1, orc6, pak2b, paqr7b, pcdh17, pdx1, pelo, phgdh, pik3ca, pitx3, pola1, polr2l, polr3d, pou2f1b, pparda, psmc1b, psmc4, ptgesl, rassf1, rchy1, rfc3, rpl13a, rpl19, rps26l, rps6kb1b, rps9, rras, sele, sirt3, slc6a4a, smad3b, snrpa, snrpd3l, snrpg, stub1, suclg2, tars, tbx1, tbx5a, tek, tfap2b, thraa, timp2b, tpm3, tpm4a, tra2a, tradd, ttk, tuba8l4, uba52, ube2d1a, ube2nb, vipr1b, vipr2, vldlr, whsc1, wls, wnt3a, zgc-55733","INCREASED BINDING OF CHEMICALS TO 2U SERUM"
"ABNORMAL RESPIRATORY SYSTEM MORPHOLOGY","24","2.53015487675952e-05","0.0467327374000725","16.33","atp6v1e1b, birc2, btk, casp8, crtap, ctsk, fgfr1a, fip1l1b, gata4, mapk1, mif, msh6, nfkb1, nos1, nras, orc6, phgdh, pola1, rras, tars, tbx1, tbx5a, tpm3, whsc1","INCREASED RESPIRATORY DISTRESS/ARREST"
"GO:0046983","29","2.55075826326482e-05","0.0372293987266968","14.72","adora2aa, adra2c, agtr1b, ahr1b, atic, cebpa, clns1a, dnm1l, drd2b, e2f3, f11r.1, fgfr1a, flot2a, gclm, h2afx, hsf1, inhbab, kars, nfkb1, pdx1, rchy1, slc6a4a, stub1, suclg2, tars, tbx1, tfap2b, tpm4a, ttk","DIMERIZATION AHR/ARNT; REDUCED DIMERIZATION ARNT/HIF1-ALPHA"
"REGULATION OF CELL DEATH","47","2.56974930691619e-05","0.0224680847087322","17.54","adora2aa, atf5b, axin2, birc2, btk, casp3b, casp8, cdk1, ctnnbl1, cyp1b1, dnm1l, e2f3, fgfr1a, gata4, gclm, hsf1, hspa5, hspa9, igf1, igf1ra, inhbab, ldha, mapk9, mif, mmp9, nfkb1, nme2b.2, nos1, nup62l, ogg1, pdx1, pik3ca, pitx3, psmc1b, psmd10, ptpn1, ptpn6, rps3a, rps6kb1b, sap18, tbx1, tek, tfap2b, thraa, tradd, uba52, wnt3a","N/A CELL INJURY/DEATH"
"RENAL TUBULAR DYSFUNCTION","3","2.63966053761534e-05","0.481254214680545","11.54","cad, ndufv2, pdx1","INCREASE HYPERPLASIA RENAL TUBULAR CELLS; INCREASE CYTOTOXICITY RENAL TUBULAR CELL; INCREASE ADENOMAS/CARCINOMAS RENAL TUBULAR; OCCURRENCE RENAL PROXIMAL TUBULAR NECROSIS"
"GO:0048870","32","2.81534354968312e-05","0.0337852690369903","16","agtr1b, CCKAR, cdk1, cyp1b1, drd1b, drd2b, f11r.1, f3a, f3b, fgfr1a, gna12a, hsd3b7, hspa5, igf1, igf1ra, insra, insrb, kars, ldha, mapk1, mif, mmp9, pik3ca, pparda, ptpn6, rps6kb1b, rras, sele, tbx1, tbx5a, tek, tradd","INCREASED MOTILITY"
"GO:0006954","19","2.85374070628492e-05","0.0552765408584042","16.24","adora2aa, agtr1b, birc2, btk, cebpa, f11r.1, f3a, f3b, igf1, kars, mif, mmp13a, mmp9, nfkb1, ogg1, pparda, sele, tek, tradd","INCREASE INFLAMMATION; INCREASE INFLAMMATION CORNEAL CELLS; INFILTRATION INFLAMMATORY CELLS; INCREASED INFLAMMATION; CHRONIC COUGH RESPIRATORY IRRITABILITY"
"GO:0046903","42","2.91655394245284e-05","0.0274012904286011","18.18","acvr2b, adora2aa, adra2c, agtr1b, atp5j, atp6v0ca, btk, cad, CCKAR, chrm2a, crhr1, cyp51, dnm1l, drd1b, drd2b, fgfr1a, foxa2, glud1a, htr2cl1, igf1, impdh1b, inhbab, kars, llgl2, mapk1, mif, mmp13a, mmp9, nfkb1, nme2b.2, nras, oprl1, pdx1, pparda, psma2, ptgesl, ptpn6, sirt3, slc6a4a, tfap2b, tuba8l4, wls","SUPPRESSION VLDL SECRETION; INCREASE MUCIN PRODUCTION; INCREASED SECRETION OF LOCAL GROWTH FACTORS"
"ABNORMALITY OF THE ABDOMINAL ORGANS","20","2.91656827757709e-05","0.0464085249365028","11.83","acvr2b, btk, casp8, cdkn1ca, ctsk, hsd3b7, insrb, mif, msh6, ndufv2, nfkb1, nras, pdx1, pik3ca, rnaseh2b, rras, stub1, tars, tbx1, whsc1","IMPAIRED DEVELOPMENT OF REPRODUCTIVE ORGANS"
"HEART DEVELOPMENT","20","3.03265188498156e-05","0.049572767268845","15.87","axin2, cad, casp3b, casp8, ddx39b, fgf3, foxa2, gata4, igf1, insrb, mapk1, ndufv2, nos1, npy2rl, slc8a1a, tbx1, tbx5a, tek, whsc1, wnt3a","ALTERED LARVAL DEVELOPMENT; IMPAIRED DEVELOPMENT"
"ABNORMAL LUNG MORPHOLOGY","22","3.03490997748092e-05","0.0489266615807256","17.19","atp6v1e1b, birc2, btk, casp8, crtap, fgfr1a, fip1l1b, gata4, mapk1, mif, nfkb1, nos1, nras, orc6, phgdh, pola1, rras, tars, tbx1, tbx5a, tpm3, whsc1","INCREASE ADENOMAS/CARCINOMAS BRONCHIOLOALVEOLAR"
"CTOME SIGNALING BY EGFR","3","3.19444188082226e-05","0.586363289765448","37.5","nras, pik3ca, uba52","ACTIVATION EGFR"
"MORTALITY AGING","6","3.31966883005088e-05","0.201102909494354","23.08","crtap, dnm1l, msh6, nras, phgdh, pik3ca","REDUCED FITNESS OR EVEN MORTALITY ACIDOSIS HYPOVOLEMIC SHOCK AND ORGAN DYSFUNCTION; INCREASE MORTALITY; INCREASED MORTALITY"
"RESPONSE TO REACTIVE OXYGEN SPECIES","11","3.35023492832555e-05","0.0659699374052833","19.64","btk, casp3b, ccna2, cyp1b1, hsf1, ldha, mapk1, mapk9, mmp9, nos1, slc8a1a","INCREASED REACTIVE OXYGEN SPECIES"
"GO:0019904","17","3.35664499174782e-05","0.06260268412383","13.82","casp8, ccna2, dnm1l, f11r.1, fgfr1a, foxa2, hspa5, insra, insrb, llgl2, nup62l, ptpn6, rps6kb1b, stub1, thraa, tradd, wnt3a","N/A INTERFERENCES WITH SH-/SELEN-PROTEINS"
"OXIDATIVE DAMAGE","3","3.39385408300888e-05","0.06745613961796","15","casp3b, cdkn1ca, nfkb1","INCREASED OXIDATIVE DAMAGE"
"GO:0009611","20","3.45268423165119e-05","0.0504593812088435","17.86","adora2aa, adra2c, casp3b, cdk1, cyp1a, drd2b, f11r.1, f3a, f3b, foxa2, gata4, gna12a, igf1, mapk1, pdx1, pik3ca, pparda, ptpn6, rps6kb1b, wnt3a","ACCUMULATION DAMAGED MITOCHONDRIAL DNA"
"GO:0007269","5","3.46965941874414e-05","0.232608429310807","20","adora2aa, chrm2a, dnm1l, drd1b, drd2b","OVERACTIVATION NEURONOTRANSMITTER RELEASE"
"GO:0004872","40","3.47741688237656e-05","0.0275116676897233","16.74","acvr2b, adora2aa, adra2c, agtr1b, CCKAR, chrm2a, chrna2b, crhr1, csf1ra, drd1b, drd2b, drd4a, f3a, f3b, fgf3, fgfr1a, fzd7a, glra4a, grik1a, htr1d, htr2cl1, igf1, igf1ra, igf1rb, inhbab, insra, insrb, npffr1l2, npy2rl, opn1lw2, opn1sw1, opn5, oprl1, paqr7b, pparda, tek, thraa, vipr1b, vipr2, wnt3a","ACTIVATION PXR/SXR"
"G TGF BETA SIGNALING PATHWAY","6","3.51325560860211e-05","0.164716462925381","8.82","acvr2b, fsta, inhbab, mapk1, ppp2r1a, rps6kb1b","ACTIVATION TGF-BETA PATHWAY; UP REGULATION TGFBETA1 EXPRESSION"
"ABNORMAL NASAL MORPHOLOGY","24","3.51463440726274e-05","0.0376000258541521","15.48","ahr1b, aldh6a1, atic, atp6v1e1b, cdkn1ca, ctsk, fgf3, fgfr1a, gata4, hspa9, igf1ra, impdh1b, insrb, lss, mapk1, mdh1aa, nras, orc6, pik3ca, ppp2r1a, rps26l, tbx1, tfap2b, whsc1","INCREASE SITE OF CONTACT NASAL TUMORS"
"GO:0006629","29","3.61537739740627e-05","0.036136208844256","14.08","agtr1b, cebpa, csnk1g2a, cyp1a, cyp1b1, cyp24a1, cyp26c1, cyp3c1, cyp51, eci2, fgfr1a, hsd11b2, hsd17b2, hsd3b7, htr2cl1, lss, mif, nfkb1, opn1lw2, opn1sw1, pgp, pik3ca, pparda, ptgesl, sirt3, stub1, tek, thraa, vldlr","ALTERATION LIPID METABOLISM"
"GO:0044414","5","3.66740420852692e-05","0.224123278617596","12.5","atp6v0ca, atp6v1c1a, atp6v1e1b, nos1, tuba8l4","SUPPRESSION IMMUNE SYSTEM"
"GO:0040011","38","3.68059843571123e-05","0.0276654832437537","16.74","adora2aa, agtr1b, CCKAR, cdk1, cyp1b1, drd1b, drd2b, f11r.1, f3a, f3b, fgfr1a, gna12a, hsd3b7, hspa5, htr1d, igf1, igf1ra, insra, insrb, kars, ldha, lhx2b, mapk1, mif, mmp9, pik3ca, pparda, ptpn6, rps6kb1b, rras, sele, tbx1, tbx5a, tek, tradd, usp14, vldlr, wnt3a","INCREASED LOCOMOTION; INCREASED MUSCULAR WAVES IN FOOT; DECREASED LOCOMOTION"
"ABNORMALITY OF THE LIVER","18","3.76397904445102e-05","0.0461170628633919","2.4","btk, casp8, cdkn1ca, ctsk, hsd3b7, insrb, mif, msh6, ndufv2, nfkb1, nras, pdx1, pik3ca, rnaseh2b, rras, tars, tbx1, whsc1","INCREASED INDUCTION OF UDPGT'S IN LIVER; INCREASED LIVER STEATOSIS; INCREASED LIVER STEATOSIS; N/A HEPATOTOXICITY HEPATOPATHY INCLUDING A CONSTELLATION OF OBSERVABLE EFFECTS; INDUCTION SUSTAINED HEPATOTOXICITY"
"GO:0001935","6","4.00577047907209e-05","0.276007201765468","16.67","agtr1b, f3a, f3b, fgfr1a, nras, tek","INCREASED PROLIFERATION ENDOTHELIAL CELLS"
"GO:0015631","3","4.08917756854705e-05","0.0440676915461819","15.79","atf5b, dnm1l, ogg1","BINDING TUBULIN"
"GO:0045444","8","4.15668899098569e-05","0.132204630059718","19.51","aldh6a1, atf5b, cebpa, htr2cl1, mmp11a, pparda, tfap2b, wnt3a","INCREASED ADIPOGENESIS"
"GO:0006636","2","4.20025351714026e-05","0.0816460083247192","16.67","mif, ptgesl","UP REGULATION UNSATURATED FATTY ACID"
"GLUTATHIONE METABOLIC PROCESS","3","4.26741462182088e-05","0.0354197334341742","30","gclm, gstk1, ptgesl","GLUTATHIONE SYNTHESIS; GLUTATHIONE HOMEOSTASIS"
"GO:0072358","16","4.33516193860073e-05","0.05945471848507","14.41","acvr2b, agtr1b, ahr1b, cyp1b1, e2f7, f3a, f3b, fgfr1a, gata4, mapk1, pik3ca, rras, tbx1, tbx5a, tek, tfap2b","ALTERED CARDIOVASCULAR DEVELOPMENT/FUNCTION"
"ABNORMAL LIVER MORPHOLOGY","13","4.35190282124254e-05","0.0504000418771152","10.92","btk, casp8, cdkn1ca, ctsk, hsd3b7, insrb, mif, ndufv2, nras, pik3ca, rnaseh2b, rras, tars","INDUCTION LIVER “DYSFUNCTIONAL” CHANGES BY CGA 330050; INFLAMMATION LIVER; N/A LIVER FIBROSIS; INCREASE RBC CONGESTION IN LIVER; INCREASE LIVER AND SPLENIC HEMOSIDEROSIS; REDUCTION VITELLOGENIN SYNTHESIS IN LIVER; INCREASE VITELLOGENIN SYNTHESIS IN LIVER; FORMATION LIVER FIBROSIS; FORMATION LIVER TUMOR"
"GO:1903409","6","4.4566141383077e-05","0.15524432624569","24","cyp1a, cyp1b1, insra, insrb, mmp13a, nos1","INCREASE ROS PRODUCTION; PRODUCTION REACTIVE OXYGEN SPECIES"
"GO:0007268","5","4.51203353306742e-05","0.226081157920434","14.29","chrm2a, chrna2b, glra4a, htr1d, htr2cl1","REDUCTION NEURONAL SYNAPTIC INHIBITION"
"CHOLESTASIS","3","4.66513994164787e-05","0.041491679533766","8.57","hsd3b7, insrb, rnaseh2b","INCREASED CHOLESTASIS; CHOLESTASIS PATHOLOGY"
"G GLUTATHIONE METABOLISM","2","4.91294560191384e-05","0.00561692172795561","25","gclm, gstk1","DEPLETION GSH"
"GO:0006936","11","5.04790090176645e-05","0.107510094123244","20","adra2c, chrm2a, drd1b, drd2b, gata4, htr1d, nos1, pik3ca, rps6kb1b, tpm3, tpm4a","REDUCTION ABDOMINAL MUSCLE CONTRACTION; OVERACTIVATION MUSCLE CONTRACTION"
"HUMAN THYROID STIMULATING HORMONE TSH SIGNALING PATHWAY","5","5.07917889041568e-05","0.0381720020222296","4.63","gna12a, igf1ra, mapk1, pik3ca, rps6kb1b","DECREASED TRIIODOTHYRONINE T3 IN SERUM; INCREASE THYROID-STIMULATING HORMONE TSH; DECREASED THYROXINE T4 IN SERUM; INCREASED THYROID-STIMULATING HORMONE TSH"
"GO:0042060","15","5.18502861933706e-05","0.0510813552126577","17.05","adora2aa, adra2c, casp3b, f11r.1, f3a, f3b, foxa2, gata4, gna12a, igf1, mapk1, pik3ca, pparda, ptpn6, wnt3a","FAILURE IN VASCULAR REPAIR MECHANISMS UNRESOLVED BLOOD LOSS HEMORRHAGE"
"GO:0003714","4","5.27997102416049e-05","0.0389815149732097","20","atf5b, e2f7, sap18, tfap2b","STABILIZATION PPAR ALPHA CO-REPRESSOR"
"GO:0003707","3","5.38364284095561e-05","0.0767461971548387","9.38","paqr7b, pparda, thraa","REDUCED MATURATION INDUCING STEROID RECEPTOR SIGNALLING OOCYTE"
"POSITIVE REGULATION OF GENE EXPRESSION","26","5.40184090184664e-05","0.0335434295064248","14.36","axin2, casp8, cyp1b1, ddx39b, drd1b, f3a, fgf3, gata4, igf1, inhbab, mapk1, mapk9, mif, mmp13a, nat10, nfkb1, nos1, polr2l, polr3d, polr3f, rps6kb1b, rps9, slc6a4a, tra2a, whsc1, wnt3a","ALTERED GENE EXPRESSION"
"SANDAL GAP","3","5.56401622960574e-05","0.0683400813388107","60","igf1ra, mapk1, pik3ca","N/A GAP"
"GO:0003824","7","5.57117714126342e-05","0.0180391263799468","10.77","atic, eci2, impdh1b, ldha, mdh1aa, ogg1, suclg2","DECREASED DHB4/HSD17B4; DECREASE INCORPORATION OF ACTIVE IODIDE INTO IODOTYROSINES; INHIBITION PROLYL HYDROXYLASES; INHIBITION UROD; DECREASE AKT/ENOS ACTIVITY; INHIBITION DEIODINASE 2; INHIBITION DEIODINASE 1; INHIBITION IODOTYROSINE DEIODINASE IYD; INHIBITION DEIODINASE 3; INHIBITION DUAL OXIDASE; INDUCTION UPREGULATION OF GLUCURONYLTRANSFERASE ACTIVITY"
"GO:0019932","15","5.70940346741072e-05","0.0736642269420116","24.59","adora2aa, adra2c, agtr1b, ahr1b, btk, crhr1, drd1b, drd2b, htr2cl1, igf1, nme2b.2, nos1, oprl1, pdx1, sele","INCREASED SECOND MESSENGER PRODUCTION"
"ABNORMAL BLOOD POTASSIUM CONCENTRATION","2","5.953400045968e-05","0.0138173408576594","16.67","hsd11b2, insrb","INCREASED BLOOD POTASSIUM CONCENTRATION"
"ABNORMAL CIRCULATING RENIN","2","5.953400045968e-05","0.0138173408576594","33.33","hsd11b2, insrb","REDUCTION GONADOTROPINS CIRCULATING CONCENTRATIONS"
"GO:0050663","4","6.09375407146931e-05","0.0505552558680311","13.33","drd2b, kars, mif, mmp13a","RELEASE CYTOKINE"
"CTOME ACTIVATION OF GENE EXPRESSION BY SREBF SREBP","2","6.74029045388571e-05","0.0660188271325912","16.67","cyp51, lss","UP REGULATION SREBF2"
"GO:0042698","4","6.81245363841056e-05","0.152987835051428","18.18","casp3b, hspa5, inhbab, oprl1","IRREGULARITIES OVARIAN CYCLE"
"GO:0099536","14","7.16784237849687e-05","0.057539381097315","12.61","adora2aa, chrm2a, dnm1l, drd1b, drd2b, grik1a, htr1d, htr2cl1, mapk1, nos1, pcdh17, slc6a4a, usp14, wnt3a","DECREASED NEURONAL NETWORK FUNCTION IN ADULT BRAIN; DECREASED NEURONAL NETWORK FUNCTION IN ADULT BRAIN"
"GO:0007612","5","7.92691510759816e-05","0.121260266070322","20.83","drd1b, drd2b, insra, insrb, oprl1","IMPAIRMENT LEARNING AND MEMORY"
"GO:0050805","4","8.14843987787237e-05","0.176812986331975","23.53","drd1b, drd2b, pcdh17, slc6a4a","INCREASED NEURONAL SYNAPTIC INHIBITION"
"GO:0006898","6","8.20627555096983e-05","0.089233734798116","15.79","drd2b, insra, insrb, sele, vldlr, wnt3a","REDUCTION VITELLOGENIN ACCUMULATION INTO OOCYTES AND OOCYTE GROWTH/DEVELOPMENT; INCREASED LDL UPTAKE"
"GO:0042446","5","8.26401137759841e-05","0.119247622457051","17.86","cyp3c1, dio1, hsd11b2, hsd17b2, nfkb1","INCREASE LUTEINIZING HORMONE LH; REPRESSED EXPRESSION OF STEROIDOGENIC ENZYMES"
"BLADDER CANCER","4","9.23263412252931e-05","0.174769223904923","9.52","mapk1, mmp9, nras, rassf1","INCREASE CANCER"
"GO:0001963","4","9.23945416427003e-05","0.168291126343339","33.33","adora2aa, drd1b, drd2b, slc6a4a","INCREASE DOPAMINERGIC ACTIVITY; DECREASED DOPAMINERGIC ACTIVITY"
"GO:0006915","3","9.26327054890139e-05","0.24045382969665","9.68","casp3b, casp8, tradd","CHANGES/INHIBITION CELLULAR HOMEOSTASIS AND APOPTOSIS; DECREASED APOPTOSIS EPITHELIAL CELLS; INCREASED APOPTOSIS DECREASED LEYDIG CELLS"
"GO:0060291","4","9.28665563256437e-05","0.167946876890479","28.57","adora2aa, drd1b, drd2b, mapk1","DECREASED LONG-TERM POTENTIATION LTP"
"GO:0007588","3","0.00011897747876833","0.263261372356688","21.43","adora2aa, agtr1b, drd2b","INCREASE BILIARY EXCRETION TH GLUCURONIDE"
"ABNORMALITY OF ADRENAL PHYSIOLOGY","4","0.000123661400434452","0.126957713130791","4.35","gata4, hsd11b2, insrb, pik3ca","INCREASE RENAL PATHOLOGY DUE TO VTG DEPOSITION; DECREASED RENAL ABILITY TO DILUTE URINE; OCCURRENCE KIDNEY TOXICITY; INCREASED KIDNEY FAILURE"
"GO:0010468","3","0.000142261830743976","0.239151712849433","18.75","lhx2b, mapk1, mapk9","DECREASED TRANSCRIPTION OF GENES BY AR"
"SYNAPTIC TRANSMISSION GLUTAMATERGIC","3","0.000166797027415469","0.219208796816036","23.08","adora2aa, drd1b, npy2rl","REDUCED PRESYNAPTIC RELEASE OF GLUTAMATE"
"LOCOMOTORY BEHAVIOR","6","0.000181470910465212","0.0926138095410813","9.68","adora2aa, drd1b, foxa2, htr2cl1, npy2rl, pitx3","REDUCED SWIMMING SPEED; REDUCED SWIMMING PERFORMANCE"
"REGULATION OF SODIUM ION TRANSPORT","2","0.000187958585345096","0.479369442595601","16.67","nos1, slc8a1a","INHIBITION SODIUM CHANNEL; MODULATION SODIUM CHANNEL"
"GO:0019098","2","0.000190759964931149","0.485888732834445","22.22","drd1b, thraa","ALTERED REPRODUCTIVE BEHAVIOUR; REDUCED BROOD CARE"
"MATING BEHAVIOR","2","0.000190759964931149","0.485888732834445","22.22","drd1b, thraa","REDUCED ABILITY TO ATTRACT SPAWNING MATES"
"REPRODUCTIVE BEHAVIOR","2","0.000190759964931149","0.485888732834445","20","drd1b, thraa","REDUCED SPAWNING BEHAVIOR"
"PEPTIDYL LYSINE MODIFICATION","4","0.000195813072895832","0.181649838845979","5.63","nos1, nup62l, sirt3, whsc1","N/A COVALENT BINDING TO PROTEIN POSSIBLY LYSINE RESIDUE"
"GO:0009653","2","0.000207746034779253","0.408654606563147","40","foxa2, pitx3","INCREASED DEVELOPMENTAL DEFECTS"
"GO:0048813","2","0.000232945916290572","0.428663856899632","15.38","dnm1l, vldlr","ABERRANT DENDRITIC MORPHOLOGY"
"G VEGF SIGNALING PATHWAY","4","0.000246327229433387","0.168662936953158","19.05","mapk1, nos1, nras, pik3ca","REDUCED PRODUCTION VEGF"
"ABNORMAL CIRCULATING ESTROGEN LEVEL","2","0.00025686400778269","0.304042080203993","14.29","gata4, pik3ca","INCREASED CIRCULATING ESTROGEN LEVELS"
"GO:0005216","3","0.000257809054204725","0.184469101675022","12.5","chrna2b, glra4a, grik1a","IMPAIRED ION CHANNELS"
"ABNORMAL PROLACTIN LEVEL","2","0.000273898860598344","0.323761146621713","25","foxa2, pik3ca","DECREASED PROLACTIN"
"ADRENERGIC RECEPTOR SIGNALING PATHWAY","2","0.000279256696240116","0.368850990972778","25","adra2c, drd1b","INCREASED ACTIVITY BETA-2 ADRENERGIC RECEPTOR; ACTIVATION BETA-2 ADRENERGIC RECEPTOR"
"GO:0042311","3","0.00035312597248229","0.23781658043741","20","adora2aa, drd1b, nos1","IMPAIRED VASODILATION"
